Authors
Kristina L Bajema, Ryan E Wiegand, Kendra Cuffe, Sadhna V Patel, Ronaldo Iachan, Travis Lim, Adam Lee, Davia Moyse, Fiona P Havers, Lee Harding, Alicia M Fry, Aron J Hall, Kelly Martin, Marjorie Biel, Yangyang Deng, William A Meyer, Mohit Mathur, Tonja Kyle, Adi V Gundlapalli, Natalie J Thornburg, Lyle R Petersen, Chris Edens
Publication date
2021/4/1
Journal
JAMA internal medicine
Volume
181
Issue
4
Pages
450-460
Publisher
American Medical Association
Description
Importance
Case-based surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely underestimates the true prevalence of infections. Large-scale seroprevalence surveys can better estimate infection across many geographic regions.
Objective
To estimate the prevalence of persons with SARS-CoV-2 antibodies using residual sera from commercial laboratories across the US and assess changes over time.
Design, Setting, and Participants
This repeated, cross-sectional study conducted across all 50 states, the District of Columbia, and Puerto Rico used a convenience sample of residual serum specimens provided by persons of all ages that were originally submitted for routine screening or clinical management from 2 private clinical commercial laboratories. Samples were obtained during 4 collection periods: July 27 to August 13, August 10 to August 27, August 24 to September 10 …
Scholar articles
KL Bajema, RE Wiegand, K Cuffe, SV Patel, R Iachan… - JAMA internal medicine, 2021